About
Bio
BioPharm Insight (BPI) is a team of investigative journalists, and owned by the Financial Times Group. The editorial team operates out of New York, London and Shanghai and covers a pipeline of events by aggregating and reviewing data about thousands of upcoming pivotal drug development events, plus equity research, Wall Street data, industry news releases, and historical coverage. The news operation is only one part of an online business intelligence system that also includes market analytics, and a database of industry contacts.
The team covers everything in healthcare, from drug development and research, partnerships/licensing, M&A, regulatory, reimbursement, medical devices, healthcare services, CROs, CMOs, among others.
The majority of their journalists have graduate degrees in the sciences, or years of scientific reporting. They are versed in understanding clinical trials data, as well as deciphering statistics. This enables BPI to uncover news and build relationship with doctors, scientists, company executives and other opinion leaders.
BioPharm Insight is published by Infinata, part of the Financial Times Group of companies and a division of Pearson plc.
BioPharm Insight does not provide user/circulation figures.
New York DMA
Email
email@cision.one
Website
site@cision.one
Social media
Location
United Kingdom
Frequency
upgrade
Circulation
upgrade
Sectors
AIDS/HIV, Allergies, Biotechnology, Cardiology, Dermatology, Diabetes, Diseases & Conditions, Gastroenterology, Healthcare Industry, Hematology, Infectious Diseases, Medical Technology, Medicine, Neurology, Occupational Therapy & Rehabilitation, Oncology, Ophthalmology & Optometry, Orthopedics, Pharmaceuticals, Public Health & Safety, Respiratory Diseases, Rheumatology, Sexual Health, Urology
Bio
BioPharm Insight (BPI) is a team of investigative journalists, and owned by the Financial Times Group. The editorial team operates out of New York, London and Shanghai and covers a pipeline of events by aggregating and reviewing data about thousands of upcoming pivotal drug development events, plus equity research, Wall Street data, industry news releases, and historical coverage. The news operation is only one part of an online business intelligence system that also includes market analytics, and a database of industry contacts. The team covers everything in healthcare, from drug development and research, partnerships/licensing, M&A, regulatory, reimbursement, medical devices, healthcare services, CROs, CMOs, among others. The majority of their journalists have graduate degrees in the sciences, or years of scientific reporting. They are versed in understanding clinical trials data, as well as deciphering statistics. This enables BPI to uncover news and build relationship with doctors, scientists, company executives and other opinion leaders. BioPharm Insight is published by Infinata, part of the Financial Times Group of companies and a division of Pearson plc. BioPharm Insight does not provide user/circulation figures. New York DMA
Website
Social media
Location
Frequency
Circulation
Sectors
AIDS/HIV, Allergies, Biotechnology, Cardiology, Dermatology, Diabetes, Diseases & Conditions, Gastroenterology, Healthcare Industry, Hematology, Infectious Diseases, Medical Technology, Medicine, Neurology, Occupational Therapy & Rehabilitation, Oncology, Ophthalmology & Optometry, Orthopedics, Pharmaceuticals, Public Health & Safety, Respiratory Diseases, Rheumatology, Sexual Health, Urology
Most recent articles by GlobalData Pharma Investigative News
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Article description
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Article description
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Article description
Explore outlets similar to GlobalData Pharma Investigative News
-
Science
Founded in 1880, with seed money from Thomas Edison, Science continues to be at the center of the very best in research across the sciences, with articles that consistently rank among the most cited in the world. Science articles are peer-reviewed, and written to appeal to both scientist and layman. Regular issue features include a news and comment section, book reviews, and coverage of scientific meetings and seminars. The News section features late-breaking news and in-depth news analysis. Compass, an opinion section, publishes letters and commentary by scientists on current science issues. The TechSight section focuses on leading edge techniques and technologies. Topics include: bioinformatics, genome sequencing, and protein sequencing. This section is published in the third issue every month. The Research section features original investigative research and reporting. Other departments include NetWatch, This Week in Science, ScienceScope, Random Samples and New Products.
ViewKFF Health NewsKaiser Health News launched in early 2009. It is an independent news service that focuses on the nation's healthcare system and related political and policy issues. The news service provides in-depth stories on developments, initiatives and debates in the healthcare system. In addition to reporting, the news service features columns, video, graphics and multimedia elements. News content is also provided online.
ViewSTAT NewsSTAT News covers health, medicine and life science news. In specific it offers coverage on the business of making medicines, health tech, science, and public health.
ViewMedscapeMedscape was created for medical specialists, primary care physicians, and health professionals and offers medical news, clinical trial information, review articles, journal commentary, expert columns, patient education articles and book reviews. It also includes Web-based services for verifying insurance information, Medline and other search engines, as well as a physician directory enabling users to find physicians by practice, location or specialty.
ViewScientific AmericanEstablished in 1845, Scientific American remains the oldest continuously-published magazine in the United States. Redesigned in October 2010, the publication covers the most important and exciting research in science, health, technology, the environment, and society, exploring important ideas often months and years before other media recognizes their importance. The magazine publishes 15 foreign language editions, and regular sections include Forum, which provides a platform for external experts to comment on science policy; Science Agenda, where editors can discuss different science issues; and Insights, which profiles a scientist or researcher and analyzes their contribution to society. Other sections include Anti Gravity and Skeptic. Regular columns include The Science of Health and TechnoFiles. Publicists should feel free to pitch anytime, although they should avoid pitching individual products or new company officer announcements. They should focus on science-based stories that are better told by a journalist than an expert.
ViewUse CisionOne to find more relevant outletsExplore journalists that write for GlobalData Pharma Investigative News
Contact us to find more relevant journalistsContact GlobalData Pharma Investigative News and get access to over 850K accurate, up-to-date media profiles.
Discover the stories that impact your brand. In realtime.
CisionOne delivers relevant news, trends and conversations that matter to your brand with the world’s most comprehensive media monitoring service across Print, Online, TV, Radio, Social, Magazines, Podcasts and more.